Cargando…

Switching from serotonin reuptake inhibitors to agomelatine in patients with refractory obsessive-compulsive disorder: a 3 month follow-up case series

BACKGROUND: Serotonin reuptake inhibitors (SRIs) currently represent the cornerstone of obsessive-compulsive disorder (OCD) pharmacotherapy. However, OCD is characterized by high rates of partial and/or absent response to standard, recommended treatments, often prompting pharmacological and non-phar...

Descripción completa

Detalles Bibliográficos
Autor principal:	Fornaro, Michele
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Primary Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3058071/ https://www.ncbi.nlm.nih.gov/pubmed/21356085 http://dx.doi.org/10.1186/1744-859X-10-5

Ejemplares similares

Effects of Celecoxib Adjunct to Selective Serotonin Reuptake Inhibitors on Obsessive-Compulsive Disorder
por: Shahini, Najmeh, et al.
Publicado: (2021)

Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: A 3-level network meta-analysis
por: Gosmann, Natan Pereira, et al.
Publicado: (2021)

Pindolol augmentation of selective serotonin reuptake inhibitors and clomipramine for the treatment of obsessive-compulsive disorder: A meta-analysis
por: Sassano-Higgins, Sean A., et al.
Publicado: (2015)

Acceptance and Commitment Therapy, Selective Serotonin Reuptake Inhibitors and Their Combination in the Improvement of Obsessive-Compulsive Symptoms and Experiential Avoidance in Patients With Obsessive-Compulsive Disorder
por: Vakili, Yaghoob, et al.
Publicado: (2015)

Lamotrigine Augmentation of Serotonin Reuptake Inhibitors in Severe and Long-Term Treatment-Resistant Obsessive-Compulsive Disorder
por: Arrojo-Romero, Manuel, et al.
Publicado: (2013)

Adjunct Triptorelin in the Treatment of Obsessive-Compulsive Disorder in Clients Receiving Selective Serotonin Reuptake Inhibitors (SSRIs)
por: Nikzad, Faezeh, et al.
Publicado: (2021)

Adjunctive therapeutic strategies in Obsessive-Compulsive Disorder resistant to serotonin reuptake inhibitors: a literature review
por: Regueira, P., et al.
Publicado: (2022)

A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine†
por: Montgomery, Stuart A, et al.
Publicado: (2014)

Cognitive Function before and during Treatment with Selective Serotonin Reuptake Inhibitors in Patients with Depression or Obsessive-Compulsive Disorder
por: Sayyah, Mehdi, et al.
Publicado: (2016)

Adding 5-hydroxytryptamine receptor type 3 antagonists may reduce drug-induced nausea in poor insight obsessive-compulsive patients taking off-label doses of selective serotonin reuptake inhibitors: a 52-week follow-up case report
por: Fornaro, Michele, et al.
Publicado: (2010)

Lamotrigine Augmentation Versus Placebo in Serotonin Reuptake Inhibitors-Resistant Obsessive-Compulsive Disorder: A Randomized Controlled Trial
por: Khalkhali, Mohammadrasoul, et al.
Publicado: (2016)

Use of Selective Serotonin Reuptake Inhibitors and Risks of Stroke in Patients with Obsessive Compulsive Disorder: A Population-Based Study
por: Chu, Che-Sheng, et al.
Publicado: (2016)

The effects of selective serotonin reuptake inhibitors on brain functional networks during goal-directed planning in obsessive–compulsive disorder
por: Kim, Minah, et al.
Publicado: (2020)

Quality of life changes following inpatient and outpatient treatment in obsessive-compulsive disorder: a study with 12 months follow-up
por: Hertenstein, Elisabeth, et al.
Publicado: (2013)

The Effectiveness of Selective Serotonin Reuptake Inhibitors for Treatment of Obsessive-Compulsive Disorder in Adolescents and Children: A Systematic Review and Meta-Analysis
por: Kotapati, Vijaya Padma, et al.
Publicado: (2019)

Optimal Dose of Serotonin Reuptake Inhibitors for Obsessive-Compulsive Disorder in Adults: A Systematic Review and Dose–Response Meta-Analysis
por: Xu, Jiao, et al.
Publicado: (2021)

Venlafaxine augmentation with agomelatine in a patient with obsessive-compulsive disorder and suicidal behaviors
por: Signorelli, Maria S, et al.
Publicado: (2014)

Selective serotonin reuptake inhibitor use associates with apathy among depressed elderly: a case-control study
por: Wongpakaran, Nahathai, et al.
Publicado: (2007)

Cognitive-Behavioral Therapy Versus Transcranial Direct Current Stimulation for Augmenting Selective Serotonin Reuptake Inhibitors in Obsessive-Compulsive Disorder Patients
por: Dadashi, Mohsen, et al.
Publicado: (2020)

Humor appreciation of captionless cartoons in obsessive-compulsive disorder
por: Bozikas, Vasilis P, et al.
Publicado: (2011)

Optimal treatment for obsessive compulsive disorder: a randomized controlled feasibility study of the clinical-effectiveness and cost-effectiveness of cognitive-behavioural therapy, selective serotonin reuptake inhibitors and their combination in the management of obsessive compulsive disorder
por: Fineberg, Naomi A., et al.
Publicado: (2018)

Agomelatine Augmentation of Escitalopram Therapy in Treatment-Resistant Obsessive-Compulsive Disorder: A Case Report
por: De Berardis, Domenico, et al.
Publicado: (2012)

Orgasm, Serotonin Reuptake Inhibition, and Plasma Oxytocin in Obsessive-Compulsive Disorder. Gleaning From a Distant Randomized Clinical Trial
por: Humble, Mats B., et al.
Publicado: (2016)

Calcium Signaling Pathway Is Associated with the Long-Term Clinical Response to Selective Serotonin Reuptake Inhibitors (SSRI) and SSRI with Antipsychotics in Patients with Obsessive-Compulsive Disorder
por: Umehara, Hidehiro, et al.
Publicado: (2016)

Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials
por: Dold, Markus, et al.
Publicado: (2015)

Efficacy of inhibitory learning theory-based exposure and response prevention and selective serotonin reuptake inhibitor in obsessive-compulsive disorder management: A treatment comparison
por: Samantaray, Narendra Nath, et al.
Publicado: (2018)

Patient satisfaction with specialized mental health service for obsessive-compulsive disorder
por: Mavrogiorgou, Paraskevi, et al.
Publicado: (2013)

Poor performance on the Iowa gambling task in children with obsessive-compulsive disorder
por: Kodaira, Masaki, et al.
Publicado: (2012)

Sentiment Analysis of Online Reviews for Selective Serotonin Reuptake Inhibitors and Serotonin–Norepinephrine Reuptake Inhibitors
por: Compagner, Chad, et al.
Publicado: (2021)

Residual sleep disturbance and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine
por: Yang, Huaiyu, et al.
Publicado: (2010)

Obsessive-compulsive disorder and related disorders: a comprehensive survey
por: Fornaro, Michele, et al.
Publicado: (2009)

Serotonin transporter gene polymorphisms & obsessive-compulsive disorder
por: Nicolini, Humberto
Publicado: (2010)

The Effect of Atorvastatin on Obsessive-compulsive Symptoms of Refractory Obsessive-compulsive Disorder (Add-on Therapy)
por: Akouchekian, Shahla, et al.
Publicado: (2018)

Aripiprazole augmentation in poor insight obsessive-compulsive disorder: a case report
por: Fornaro, Michele, et al.
Publicado: (2008)

SUCCESSFUL TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER WITH ZIMELIDINE, A SEROTONIN RE-UPTAKE INHIBITOR
por: Prasad, Ashoka
Publicado: (1983)

What happens next?: a claims database study of second-line pharmacotherapy in patients with major depressive disorder (MDD) who initiate selective serotonin reuptake inhibitor (SSRI) treatment
por: Ball, Susan, et al.
Publicado: (2014)

Neuroablative Intervention for Refractory Obsessive-Compulsive Disorder
por: Chang, Jhin Goo, et al.
Publicado: (2023)

Clinical pharmacology of serotonin selective reuptake inhibitors /
por: Preskorn, Sheldon
Publicado: (1996)

Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia
por: Welsch, Patrick, et al.
Publicado: (2018)

Selective serotonin reuptake inhibitors and Alzheimer’s disease
por: Mdawar, Bernadette, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2lbkcnqlbdgm00vhrrdhnefg60